EVOK - Evoke Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.05
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.05
Open3.05
Bid1.90 x 800
Ask3.25 x 1100
Day's Range2.95 - 3.10
52 Week Range1.85 - 4.09
Volume114,133
Avg. Volume95,519
Market Cap51.163M
Beta3.22
PE Ratio (TTM)N/A
EPS (TTM)-0.90
Earnings DateMay 14, 2018 - May 18, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.80
Trade prices are not sourced from all markets
  • Evoke Pharma Inc (NASDAQ:EVOK) Is Expected To Breakeven
    Simply Wall St.7 days ago

    Evoke Pharma Inc (NASDAQ:EVOK) Is Expected To Breakeven

    Evoke Pharma Inc’s (NASDAQ:EVOK): Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. On 31 December 2017,Read More...

  • GlobeNewswire8 days ago

    Evoke Pharma Reports First Quarter 2018 Results and Highlights

    NDA submission for Gimoti™ on track for second quarter of 2018 Announced discovery of sex-based pharmacokinetic differences for Gimoti Waiver of the PDUFA fee for Gimoti NDA granted by FDA Cash runway ...

  • GlobeNewswire12 days ago

    Evoke Granted Gender Specific Patent for Gimoti™ in Mexico

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Mexican Institute of Industrial Property has issued a Notice that it intends to grant Mexican Patent Application MX/a/2014/002125 for Gimoti, covering uses of metoclopramide for intranasal delivery for the treatment of symptoms associated with diabetic gastroparesis specifically for women. “This is the second allowance from our estate of international patent applications directed toward female specific intellectual property in gastroparesis,” commented Dave Gonyer, President and CEO. “The studies we have conducted have shown significant differences in how to treat patients with gastroparesis.

  • GlobeNewswire22 days ago

    Evoke Granted First Gender Specific Patent for Gimoti™

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that the European Patent Office has issued a Decision to Grant European Union (EU) patent no. 2747561 for Gimoti™, covering formulations of metoclopramide for intranasal delivery for the treatment of symptoms associated with diabetic gastroparesis specifically for women. The notice confirms that the patent grant applies to 38 covered member states and will be published on May 9, 2018 with patent expiry extended to 2032. “This patent represents the first female specific intellectual property approved for Gimoti and highlights the significant work we’ve accomplished in developing this novel new treatment for gastroparesis,” commented Dave Gonyer, President and CEO.

  • GlobeNewswire2 months ago

    Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments

    SOLANA BEACH, Calif., March 26, 2018-- Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal d­­ iseases, today announced that it has amended the Company’ s ...

  • GlobeNewswire2 months ago

    Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights

    Successfully completed pivotal pharmacokinetic trial and finalized the proposed to-be-marketed Gimoti™ dose Announced discovery of sex-based pharmacokinetic differences for Gimoti™ Met with FDA regarding ...

  • ACCESSWIRE2 months ago

    Evoke Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Evoke Pharma, Inc. (NASDAQ: EVOK ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018 at 4:30 PM Eastern Time. To ...

  • GlobeNewswire3 months ago

    Evoke Pharma to Present at the Upcoming Roth and Oppenheimer Investor Conferences

    SOLANA BEACH, Calif., March 06, 2018-- Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal d­­ iseases, today announced that Dave Gonyer, President and Chief ...

  • GlobeNewswire3 months ago

    FDA Approves PDUFA Fee Waiver for Gimoti™ New Drug Application

    SOLANA BEACH, Calif., March 05, 2018-- Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal d­­ iseases, today announced that the U.S. Food and Drug Administration ...

  • GlobeNewswire3 months ago

    Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial Results

    SOLANA BEACH, Calif., Feb. 21, 2018-- Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial ...

  • ACCESSWIRE5 months ago

    Wired News – Akari’s Phase-II COBALT Trial of Coversin in Patients with PNH Met the Primary Endpoint

    Stock Monitor: Evoke Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 12, 2017 / Active-Investors issued a free report on Akari Therapeutics, PLC (NASDAQ: AKTX ), which is readily accessible ...

  • ACCESSWIRE5 months ago

    Wired News – SteadyMed Reported FDA Agreed Pathway to Trevyent NDA Resubmission

    Stock Monitor: Evoke Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 11, 2017 / Active-Investors issued a free report on SteadyMed Ltd (NASDAQ: STDY ), which is readily accessible upon ...

  • ACCESSWIRE6 months ago

    Evoke Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Evoke Pharma, Inc. (EXCHANGE: EVOK ) will be discussing their earnings results in their Q3 Earnings Call to be held on Tuesday, November 14, 2017 at 4:30 ...

  • A Look At Evoke Pharma Inc (EVOK) And The Healthcare Sector
    Simply Wall St.6 months ago

    A Look At Evoke Pharma Inc (EVOK) And The Healthcare Sector

    Evoke Pharma Inc (NASDAQ:EVOK), a USD$43.09M small-cap, is a healthcare company operating in an industry, which continues to endure a more demanding healthcare agenda, and the global need for innovative,Read More...

  • ACCESSWIRE9 months ago

    Investor Network: Evoke Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2017 / Evoke Pharma, Inc. (NASDAQ: EVOK ) will be discussing their earnings results in their Q2 Earnings Call to be held on Monday, August 14, 2017 at 4:30 PM Eastern ...